Bharat Serums AND Vaccines Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bharat Serums AND Vaccines Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $40.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bharat Serums AND Vaccines Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $40.1M Trade | TransData Nexus

Bharat Serums AND Vaccines Limited

Indian Pharmaceutical Exporter · Other Specialist · $40.1M Total Trade · DGFT Verified

Bharat Serums AND Vaccines Limited is an Indian pharmaceutical exporter with a total trade value of $40.1M across 4 products in 3 therapeutic categories. Based on 853 verified export shipments from Indian Customs (DGFT) records, Bharat Serums AND Vaccines Limited is the #1 Indian exporter in 2 products including Amphotericin, Serum. Top exports include Immunoglobulin ($16.4M), Amphotericin ($15.8M), Serum ($6.5M).

Bharat Serums AND Vaccines Limited — Export Portfolio & Destination Treemap

Bharat Serums AND Vaccines Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bharat Serums AND Vaccines Limited? — Company Overview & Market Position

Bharat Serums and Vaccines Limited (BSV) is a prominent biopharmaceutical company based in India, specializing in the development and manufacturing of biological, biotech, and pharmaceutical products. Established in 1971, BSV has over five decades of experience in the industry, focusing on therapeutic areas such as women's health, critical care, and assisted reproductive technology (IUI-IVF).

The company's registered office is located at 3rd Floor, Liberty Tower, Plot No. K-10, Behind Reliable Plaza, Kalwa Industrial Estate, Airoli, Navi Mumbai, Maharashtra 400 708, India. BSV operates as a public unlisted company, with a Corporate Identification Number (CIN) of U24230MH1971PLC015134. As of the latest available data, the company employs approximately 2,366 individuals.

What Does Bharat Serums AND Vaccines Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin$16.4M 2Amphotericin

Product Portfolio — Top 4 by Export Value

Bharat Serums AND Vaccines Limited exports 4 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$16.4M	329	9.1%	2
2	Amphotericin	Antifungals	$15.8M	315	17.9%	1
3	Serum	Other	$6.5M	131	24.1%	1
4	Folic	Nutritional Supplements	$1.3M	78	2.4%	9

Bharat Serums AND Vaccines Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $40.1M. The company is the #1 Indian exporter in 2 products: Amphotericin, Serum. The top category is Other (57.4% of portfolio), followed by Antifungals (39.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Bharat Serums AND Vaccines Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

BSV operates multiple manufacturing facilities in India, including WHO-GMP certified plants in Maharashtra and PICS-approved facilities in Brazil. These facilities are equipped to produce a diverse range of pharmaceutical formulations, including injectables, novel drug delivery systems, and biologicals.

3Key Leadership

The leadership team at BSV includes:

Bharat V. Daftary: Chairman & Managing Director

Sanjiv Hari Navangul: Chief Executive Officer (appointed on 7 February 2025)

Chirag Ashokbhai Mehta: Chief Financial Officer and Head of Legal & IT (appointed on 22 September 2021)

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bharat Serums AND Vaccines Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

BSV has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained various regulatory approvals, such as WHO-GMP certifications for its manufacturing facilities, enabling access to these markets. Additionally, BSV has a wholly owned subsidiary in the United States, indicating a strategic approach to market penetration.

2Emerging Markets

BSV has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO prequalification and EU GMP certifications have facilitated access to these regions, allowing BSV to offer its products to a broader patient base.

3Geographic Strategy

BSV's geographic strategy demonstrates a balanced approach, with a strong presence in both regulated and emerging markets. The company's diversification across various regions mitigates concentration risk and aligns with its strategic direction to enhance global accessibility to its products.

Bharat Serums AND Vaccines Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

BSV's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), and the company has filed Abbreviated New Drug Applications (ANDAs) for its products. The facilities have undergone FDA inspections, ensuring compliance with U.S. regulatory standards. BSV's adherence to FDA requirements underscores its commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

BSV's manufacturing facilities hold WHO-GMP certifications, affirming compliance with international quality standards. The company also possesses EU GMP certificates, enabling it to market its products within the European Union. These certifications reflect BSV's dedication to producing high-quality pharmaceutical formulations.

3CDSCO & Indian Regulatory

BSV holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India, authorizing the production of pharmaceutical formulations. The company has obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

Bharat Serums AND Vaccines Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

BSV operates in a competitive landscape with several key players in the biopharmaceutical industry. Top competitors include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. BSV's focus on specialized therapeutic areas such as women's health, critical care, and IUI-IVF differentiates it from competitors, allowing it to carve out a niche in the market.

2Key Differentiators

BSV's unique strengths include its extensive product portfolio, which encompasses plasma derivatives, monoclonals, fertility hormones, antifungals, anesthetics, cardiovascular drugs, and equine immunoglobulin/antitoxins. The company's commitment to research and development, with a dedicated center housing over 60 scientists, drives innovation and addresses unmet medical needs.

3Strategic Position

BSV's current strategic direction focuses on expanding its presence in generics, specialty pharmaceuticals, and biosimilars. The company's robust R&D capabilities and regulatory certifications position it well for future growth in these areas. BSV's strategic initiatives aim to enhance its global footprint and deliver innovative healthcare solutions to a broader patient population.

Buyer Due Diligence Brief — Evaluating Bharat Serums AND Vaccines Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

BSV has a strong track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $40.1 million USD across 853 shipments. The company's portfolio includes four products across three therapeutic categories, with a concentration in antifungals and other categories. BSV's consistent export volume and adherence to international quality standards underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering BSV as a supplier:

FDA Facility Registration: Confirm the registration status of BSV's manufacturing facilities with the U.S. FDA.

WHO-GMP Certification: Ensure that BSV's manufacturing facilities hold valid WHO-GMP certifications.

EU GMP Certification: Verify the EU GMP certification status of BSV's manufacturing facilities.

Frequently Asked Questions — Bharat Serums AND Vaccines Limited

How many pharmaceutical products does Bharat Serums AND Vaccines Limited export from India?

Bharat Serums AND Vaccines Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Immunoglobulin ($16.4M), Amphotericin ($15.8M), Serum ($6.5M), Folic ($1.3M). Total export value is $40.1M.

What is Bharat Serums AND Vaccines Limited's total pharmaceutical export value?

Bharat Serums AND Vaccines Limited's total pharmaceutical export value is $40.1M, based on 853 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Bharat Serums AND Vaccines Limited the #1 Indian exporter?

Bharat Serums AND Vaccines Limited is the #1 Indian exporter in 2 products: Amphotericin (17.9% market share), Serum (24.1% market share).

What therapeutic categories does Bharat Serums AND Vaccines Limited cover?

Bharat Serums AND Vaccines Limited exports across 3 therapeutic categories. The largest are Other (57.4%, 2 products), Antifungals (39.3%, 1 products), Nutritional Supplements (3.3%, 1 products).

Get Full Bharat Serums AND Vaccines Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.